These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1028 related articles for article (PubMed ID: 36153580)
1. APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer's disease pathology and brain diseases. Fernández-Calle R; Konings SC; Frontiñán-Rubio J; García-Revilla J; Camprubí-Ferrer L; Svensson M; Martinson I; Boza-Serrano A; Venero JL; Nielsen HM; Gouras GK; Deierborg T Mol Neurodegener; 2022 Sep; 17(1):62. PubMed ID: 36153580 [TBL] [Abstract][Full Text] [Related]
2. Differential Signaling Mediated by ApoE2, ApoE3, and ApoE4 in Human Neurons Parallels Alzheimer's Disease Risk. Huang YA; Zhou B; Nabet AM; Wernig M; Südhof TC J Neurosci; 2019 Sep; 39(37):7408-7427. PubMed ID: 31331998 [TBL] [Abstract][Full Text] [Related]
3. Humanized APOE genotypes influence lifespan independently of tau aggregation in the P301S mouse model of tauopathy. Williams T; Bathe T; Vo Q; Sacilotto P; McFarland K; Ruiz AJ; Hery GP; Sullivan P; Borchelt DR; Prokop S; Chakrabarty P Acta Neuropathol Commun; 2023 Jun; 11(1):99. PubMed ID: 37337279 [TBL] [Abstract][Full Text] [Related]
4. APOE modulates the effect of estrogen therapy on Aβ accumulation EFAD-Tg mice. Kunzler J; Youmans KL; Yu C; Ladu MJ; Tai LM Neurosci Lett; 2014 Feb; 560():131-6. PubMed ID: 24368217 [TBL] [Abstract][Full Text] [Related]
5. Impact of APOE genotype on prion-type propagation of tauopathy. Williams T; Ruiz AJ; Ruiz AM; Vo Q; Tsering W; Xu G; McFarland K; Giasson BI; Sullivan P; Borchelt DR; Chakrabarty P Acta Neuropathol Commun; 2022 Apr; 10(1):57. PubMed ID: 35440098 [TBL] [Abstract][Full Text] [Related]
6. Interaction of nascent ApoE2, ApoE3, and ApoE4 isoforms expressed in mammalian cells with amyloid peptide beta (1-40). Relevance to Alzheimer's disease. Aleshkov S; Abraham CR; Zannis VI Biochemistry; 1997 Aug; 36(34):10571-80. PubMed ID: 9265639 [TBL] [Abstract][Full Text] [Related]
7. Plasma ApoE4 Levels Are Lower than ApoE2 and ApoE3 Levels, and Not Associated with Plasma Aβ40/42 Ratio as a Biomarker of Amyloid-β Amyloidosis in Alzheimer's Disease. Nakamura T; Kawarabayashi T; Ueda T; Shimomura S; Hoshino M; Itoh K; Ihara K; Nakaji S; Takatama M; Ikeda Y; Shoji M J Alzheimers Dis; 2023; 93(1):333-348. PubMed ID: 36970894 [TBL] [Abstract][Full Text] [Related]
8. APOE genotype and sex affect microglial interactions with plaques in Alzheimer's disease mice. Stephen TL; Cacciottolo M; Balu D; Morgan TE; LaDu MJ; Finch CE; Pike CJ Acta Neuropathol Commun; 2019 May; 7(1):82. PubMed ID: 31113487 [TBL] [Abstract][Full Text] [Related]
9. Trem2 deficiency differentially affects phenotype and transcriptome of human APOE3 and APOE4 mice. Fitz NF; Wolfe CM; Playso BE; Biedrzycki RJ; Lu Y; Nam KN; Lefterov I; Koldamova R Mol Neurodegener; 2020 Jul; 15(1):41. PubMed ID: 32703241 [TBL] [Abstract][Full Text] [Related]
10. APOE4 is a Risk Factor and Potential Therapeutic Target for Alzheimer's Disease. Ayyubova G CNS Neurol Disord Drug Targets; 2024; 23(3):342-352. PubMed ID: 36872358 [TBL] [Abstract][Full Text] [Related]
11. Apolipoprotein E and oxidative stress in brain with relevance to Alzheimer's disease. Butterfield DA; Mattson MP Neurobiol Dis; 2020 May; 138():104795. PubMed ID: 32036033 [TBL] [Abstract][Full Text] [Related]
12. Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls. Martínez-Morillo E; Hansson O; Atagi Y; Bu G; Minthon L; Diamandis EP; Nielsen HM Acta Neuropathol; 2014 May; 127(5):633-43. PubMed ID: 24633805 [TBL] [Abstract][Full Text] [Related]
13. Association of APOE e2 genotype with Alzheimer's and non-Alzheimer's neurodegenerative pathologies. Goldberg TE; Huey ED; Devanand DP Nat Commun; 2020 Sep; 11(1):4727. PubMed ID: 32948752 [TBL] [Abstract][Full Text] [Related]
14. Selective reduction of astrocyte apoE3 and apoE4 strongly reduces Aβ accumulation and plaque-related pathology in a mouse model of amyloidosis. Mahan TE; Wang C; Bao X; Choudhury A; Ulrich JD; Holtzman DM Mol Neurodegener; 2022 Feb; 17(1):13. PubMed ID: 35109920 [TBL] [Abstract][Full Text] [Related]
15. APOE-ε4 synergizes with sleep disruption to accelerate Aβ deposition and Aβ-associated tau seeding and spreading. Wang C; Nambiar A; Strickland MR; Lee C; Parhizkar S; Moore AC; Musiek ES; Ulrich JD; Holtzman DM J Clin Invest; 2023 Jul; 133(14):. PubMed ID: 37279069 [TBL] [Abstract][Full Text] [Related]
16. APOE and Alzheimer's Disease: Evidence Mounts that Targeting APOE4 may Combat Alzheimer's Pathogenesis. Uddin MS; Kabir MT; Al Mamun A; Abdel-Daim MM; Barreto GE; Ashraf GM Mol Neurobiol; 2019 Apr; 56(4):2450-2465. PubMed ID: 30032423 [TBL] [Abstract][Full Text] [Related]
17. Apolipoprotein E level and cholesterol are associated with reduced synaptic amyloid beta in Alzheimer's disease and apoE TR mouse cortex. Arold S; Sullivan P; Bilousova T; Teng E; Miller CA; Poon WW; Vinters HV; Cornwell LB; Saing T; Cole GM; Gylys KH Acta Neuropathol; 2012 Jan; 123(1):39-52. PubMed ID: 22020632 [TBL] [Abstract][Full Text] [Related]
19. Total Cholesterol and APOE-Related Risk for Alzheimer's Disease in the Alzheimer's Disease Neuroimaging Initiative. Dunk MM; Driscoll I; J Alzheimers Dis; 2022; 85(4):1519-1528. PubMed ID: 34958023 [TBL] [Abstract][Full Text] [Related]
20. The Important Interface Between Apolipoprotein E and Neuroinflammation in Alzheimer's Disease. Kloske CM; Wilcock DM Front Immunol; 2020; 11():754. PubMed ID: 32425941 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]